Press Releases For all investor or media inquiries, visit https://www.adaptimmune.com/contact. Year All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | May 11, 2023 TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 08, 2023 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2023 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 23, 2023 TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update Mar 06, 2023 Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Feb 08, 2023 TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023 Jan 05, 2023 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 05, 2023 TCR² Therapeutics Announces Pipeline Priorities for 2023